#395 – Brain Lipidology: Understanding APOE, Cholesterol Homeostasis, Alzheimer’s Disease Risk, and the Effects of Lipid-Lowering Therapies on Brain Health |...
In a deep‑dive episode of The Drive, lipidologist Tom Dayspring explains how the brain’s cholesterol system operates largely independent of peripheral lipoproteins. He outlines the roles of apoB, apoA‑I and especially apoE in cholesterol transport, and how APOE genotype drives Alzheimer’s disease risk through amyloid and tau pathways. Dayspring also reviews current evidence on statins, ezetimibe, omega‑3 fatty acids, and emerging CETP inhibitors for brain health, highlighting both known benefits and lingering uncertainties.
The Beginning of the End of Atherosclerosis?
PCSK9 inhibitors have dramatically lowered LDL‑C and cardiovascular events, but require ongoing dosing. Eli Lilly’s VERVE‑102 uses base‑editing gene therapy to permanently disable the PCSK9 gene, delivering a single intravenous infusion. In a Phase I study of 35 high‑risk patients, LDL‑C fell...
#394 ‒ Sleep Pharmacology: The Role of Medications in Healthy Sleep, the Promise of Emerging Therapies, and the Evidence for...
In a deep‑dive episode, Peter Attia examines sleep pharmacology, positioning prescription drugs as targeted tools rather than the primary solution for insomnia. He outlines the four core drivers of sleep problems—pressure, circadian timing, hyperarousal, and architecture—and matches each medication class...
Resistance Training: Lowering the Barrier to Entry
Resistance training is essential for healthy aging, yet most adults avoid it because conventional programs demand heavy loads, frequent sessions, and training to failure. A 2023 meta‑analysis of 192 studies on untrained adults found that a moderate‑load, multiple‑set routine performed...
Growth Hormone for Musculoskeletal System Repair
Human growth hormone (hGH) is heavily promoted for tissue repair, anti‑aging and performance enhancement, yet robust clinical evidence in non‑deficient adults is lacking. While GH replacement is effective for documented deficiency and severe catabolic states, trials show only modest, inconsistent...
#393 ‒ AMA #85: A Guide to Medications and Supplements: Determining What to Take, What to Skip, and How to...
In this AMA, Peter Attia explains how to evaluate medications and supplements by first precisely defining a health problem with measurable metrics, targets, and timelines, rather than starting with a desired outcome. He stresses that the intended purpose of an...
#392 – Genetic Testing: When It’s Valuable, How to Choose the Right Test, and What to Do with the Results
Peter Attia breaks down the hype and reality of genetic testing, explaining that while DNA sequencing is now cheap and widely available, its ability to predict disease risk is often probabilistic rather than deterministic. He highlights scenarios where testing can...
#391 ‒ Colorectal Cancer Screening: Importance of Early Screening, Colonoscopy as a Screening and Preventive Tool, and How to Build...
In this episode Peter Attia explains why colorectal cancer is the most preventable major cancer and walks listeners through the biology, screening options, and personalized strategies for early detection. He highlights colonoscopy’s unique dual role as a diagnostic and therapeutic...
#390 ‒ AMA #84: Family Health History, Preventing Heart Disease, Metabolic Health, Strength Training Efficiency, Dementia Risk Reduction, NAD Supplements,...
In this AMA, Peter Attia tackles listener questions on building a useful family health history, cardiovascular risk assessment, and why heart disease remains poorly prevented despite available tools. He discusses the concept of metabolically healthy obesity, outlines the minimum effective...
Reducing Cardiovascular Risk: A Playbook for Lipid-Lowering Pharmacotherapy
The episode outlines a practical decision‑making framework for lipid‑lowering pharmacotherapy, emphasizing that the key question is not whether to treat high LDL‑C but how to choose the optimal therapy. It explains how to assess baseline labs, identify the dominant cholesterol...
#389 – Thinking Scientifically: Why It’s Hard, Why It Matters, and a Practical Toolkit
In a special episode, Peter Attia breaks down scientific thinking as a disciplined approach to evaluating any claim, not just laboratory work. He explains why humans struggle with this mindset, citing cognitive biases and the tendency to favor certainty over...
There Is No Safe Gamble with High LDL Cholesterol
The article challenges the claim from the documentary *The Cholesterol Code* that “lean‑mass hyper‑responders” (LMHRs) on low‑carbohydrate, high‑fat diets can sustain extremely high LDL‑C without added atherosclerotic risk. It explains that LDL‑C is a proxy for apoB particle number, the...
Prostate Cancer: A PSA on PSA
Prostate cancer mortality is stalling as advanced‑stage diagnoses climb in the United States and Canada, a trend linked to the 2008‑2012 USPSTF move away from routine PSA screening. New evidence shows that refined PSA strategies—tracking PSA velocity and PSA density—combined...
#387 – AMA #83: Peptides—Evaluating the Science, Safety, and Hype in a Rapidly Growing Field
Peter’s AMA on gray‑market peptides demystifies a fast‑growing, often misunderstood segment of the wellness industry. He introduces a four‑point framework—mechanism, evidence, safety, and regulatory status—to assess any peptide claim. The episode walks through real‑world case studies such as SS‑31, melanotan‑II,...
Research Worth Sharing, April 2026 Edition
The April 2026 edition of “Research Worth Sharing” spotlights four breakthrough studies: paternal endurance exercise boosts offspring VO₂ max via sperm‑borne microRNAs; SARS‑CoV‑2 mRNA vaccination within 100 days of immune‑checkpoint inhibitor therapy cuts mortality in NSCLC and melanoma, especially in immunologically cold tumors;...